Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PARP Inhibitors in Breast Cancer: a Short Communication
Gordon R. Daly, Maen Monketh Alrawashdeh, Jason McGrath, et al.
Current Oncology Reports (2024) Vol. 26, Iss. 2, pp. 103-113
Open Access | Times Cited: 10

Showing 10 citing articles:

The Landscape of PARP Inhibitors in Solid Cancers
Marta Muzzana, Massimo Broggini, Giovanna Damia
OncoTargets and Therapy (2025) Vol. Volume 18, pp. 297-317
Open Access | Times Cited: 1
Poly (adenosine diphosphate‐ribose) polymerase inhibitors in the treatment of triple‐negative breast cancer with homologous repair deficiency
Peng Yuan, Nan Ma, Binghe Xu
Medicinal Research Reviews (2024) Vol. 44, Iss. 6, pp. 2774-2792
Open Access | Times Cited: 6
Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape
Gordon R. Daly, Sindhuja Naidoo, Mohammad Alabdulrahman, et al.
Current Oncology Reports (2024) Vol. 26, Iss. 8, pp. 890-903
Open Access | Times Cited: 4
Substitutions at the C-8 position of quinazolin-4-ones improve the potency of nicotinamide site binding tankyrase inhibitors
Chiara Bosetti, Dionysis Kampasis, Shoshy Alam Brinch, et al.
European Journal of Medicinal Chemistry (2025) Vol. 288, pp. 117397-117397
Open Access
Novel Strategies in Breast Cancer Management: from Treatment to Long-term Remission
S Habibi, Shabbou Bahramian, Saeedeh Zare Jalise, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104715-104715
Closed Access
PARP Inhibitors in the Neoadjuvant Setting; A Comprehensive Overview of the Rationale for their Use, Past and Ongoing Clinical Trials
Minatoullah Habaka, Gordon R. Daly, Deborah Shinyanbola, et al.
Current Oncology Reports (2025)
Open Access
Immunotherapeutic effects of de novo benzimidazole derivative and prebiotic bacterial levan against triple-negative breast tumors by harnessing the immune landscape to intercept the oncogenic transcriptome
Heba Shawky, Dalia B. Fayed, Somaia S. Abd El‐Karim, et al.
International Journal of Biological Macromolecules (2024) Vol. 289, pp. 138844-138844
Closed Access | Times Cited: 1
Effect of Eight Weeks of Resistance Training on Fatigue, Quality of Life, and Body Composition of Metastatic Breast Cancer Patients: A Clinical Trial
Somayeh Nazari, N Behpour, Behrooz Gharib
Deleted Journal (2024) Vol. 17, Iss. 1, pp. 4-21
Closed Access
Somatic and germline aberrations in homologous recombination repair genes among Chinese high-risk breast cancer patients by multi-gene next-generation sequencing
Ling Ling Xie, Jie Chen, YanYing Zheng, et al.
Clinical & Translational Oncology (2024)
Closed Access
Substitutions at the C-8 position of quinazolin-4-ones improve the potency of nicotinamide site binding tankyrase inhibitors
Chiara Bosetti, Dionisis Kampasis, Albert Galera‐Prat, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Page 1

Scroll to top